Ind-Swift Laboratories Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights

Ind-Swift Laboratories Q4 FY26 results were declared on May 28, 2026. The company reported net profit of Rs 15.1 crore for the quarter ended March 31, 2026, +37.3% YoY. Revenue from operations was Rs 170 crore, +14.9% YoY. Results are on a standalone basis. Ind-Swift Laboratories is a Active Pharmaceutical Ingredients (API) company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Ind-Swift Laboratories Q4 FY26 Financial Highlights

Note: Q4 FY26 PAT Rs 15.1 Cr (+37.3% YoY from Rs 11 Cr). Revenue Rs 170 Cr (+14.9% YoY). Strong API exports drove revenue and margin improvement. Always verify from BSE/NSE audited filings before investment decisions.

Ind-Swift Laboratories Q4 FY26 Performance Analysis

The Ind-Swift Laboratories Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue grew to Rs 170 crore, +14.9% YoY. Net profit of Rs 15.1 crore reflects the company’s operational efficiency. Ind-Swift Laboratories operates in the Active Pharmaceutical Ingredients (API) sector.

India’s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. The Active Pharmaceutical Ingredients (API) sector benefited from these structural tailwinds during the January to March 2026 quarter.

Key Business Factors in Q4 FY26

Revenue and Volume Performance

Revenue from operations grew to Rs 170 crore, +14.9% YoY in Ind-Swift Laboratories Q4 FY26. The Active Pharmaceutical Ingredients (API) sector benefited from India’s domestic demand recovery and infrastructure push in FY26.

Profitability and Margin Trajectory

Q4 FY26 net profit of Rs 15.1 crore demonstrates strong profitability.

Sector and Macro Backdrop

India’s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported business investment and consumer spending. The Active Pharmaceutical Ingredients (API) sector benefited from these structural tailwinds during the quarter ended March 31, 2026.

Dividend Details

No dividend was declared for Q4 FY26. The company channelled resources towards operational growth in Q4 FY26.

FY27 Outlook

Following the Ind-Swift Laboratories Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Execution against strategic priorities in FY27 will be critical for sustained performance. India’s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Ind-Swift Laboratories in FY27.

Ind-Swift Laboratories Stock Performance

Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.

Shares of Ind-Swift Laboratories are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.

Key Risks

Revenue and Demand Risk

Any deceleration in India’s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Ind-Swift Laboratories’s products and services in the Active Pharmaceutical Ingredients (API) sector in FY27.

Margin and Cost Volatility

Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability from Q4 FY26 levels.

Regulatory and Competitive Risk

Changes in regulatory frameworks, competitive pressure from domestic and global peers, and customer concentration risks are key watchpoints for Ind-Swift Laboratories investors in FY27.

Conclusion

Ind-Swift Laboratories Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 15.1 crore, +37.3% YoY. The results reflect the company’s execution capability heading into FY27. Investors should monitor management guidance and sector trends before making investment decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.

Frequently Asked Questions on Ind-Swift Laboratories Q4 FY26 Results

What is Ind-Swift Laboratories Q4 FY26 net profit?

Ans. Ind-Swift Laboratories Q4 FY26 net profit was Rs 15.1 crore, +37.3% YoY. Results declared May 28, 2026.

What is Ind-Swift Laboratories Q4 FY26 revenue?

Ans. Ind-Swift Laboratories Q4 FY26 revenue was Rs 170 crore, +14.9% YoY.

When were Ind-Swift Laboratories Q4 FY26 results declared?

Ans. Ind-Swift Laboratories Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.

What dividend did Ind-Swift Laboratories declare for FY26?

Ans. No dividend was declared for Q4 FY26. Verify from BSE/NSE filings for record date and payout schedule.

What is the FY27 outlook for Ind-Swift Laboratories?

Ans. Following Ind-Swift Laboratories Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.

Is Ind-Swift Laboratories a good buy after Q4 FY26 results?

Ans. Investment decisions in Ind-Swift Laboratories require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.

What sector does Ind-Swift Laboratories operate in?

Ans. Ind-Swift Laboratories operates in the Active Pharmaceutical Ingredients (API) sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.